/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA/
TORONTO, March 24, 2020 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced updated plans for its annual and special meeting of shareholders (the "Meeting"). SQI will host the Meeting on Tuesday, March 31, 2020 at 1 p.m. (Toronto time) by conference call only (details below).
The decision to no longer host the Meeting in-person reflects SQI's efforts to contain the spread of the COVID-19 coronavirus and prioritize and support the well-being of our shareholders and colleagues. Shareholders will be able to listen and ask questions, but will not be able to vote during the Meeting.
SQI encourages registered and beneficial shareholders who have not already voted to vote in advance of the Meeting by depositing proxies or submitting voting instruction forms online at www.investorvote.com or by telephone at 1-866-732-VOTE (8683) toll free. The deadline to vote your proxy in advance of the Meeting is 11:00 a.m. (Toronto time) on Friday, March 27, 2020.
Shareholders may use the following information to listen to the Meeting via conference call. Callers will be asked for their name upon dialing into the conference call and to identify whether they are a shareholder.
Toll-Free: 1-800-504-8071 or 647-723-3983
Access Code: 1342414
We regret that we cannot meet in person this year. We thank our shareholders in advance for their support of these precautionary measures and for their patience as we work through this format.
The Company also wishes to announce that Morlan Reddock has been appointed as the Company's Vice President of Finance, effective March 23, 2020, replacing Ms. Leslie Auld who served as Vice President of Finance since January 15, 2020 on an interim basis.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit www.sqidiagnostics.com.
Interim Chief Executive Officer
416.674.9500 ext. 242
Vice President of Finance
416.674.9500 ext. 277
This press release contains certain words and statements, which may constitute "forward-looking statements" within the meaning of applicable securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties detailed in the Company's ongoing filings with the securities regulatory authorities, available to the public at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE SQI Diagnostics Inc.